The nonsteroidal anti-inflammatory drugs (NSAIDs) are believed to mediate their anticancer effects by inducing apoptosis but the molecular mechanisms of their apoptotic effects remain largely unknown. Here we report that two different NSAIDs, sulindac sulfide and SC-'236 engage the death receptor 5 (DR5) and mitochondrial pathways to mediate apoptosis in human colon cancer cells. We show that sulindac sulfide and SC-'236-induced apoptosis is coupled with upregulation of DR5, caspase 8 activation and Bid cleavage. Thus, a cross talk appears to exist between the DR5 and mitochondrial pathways during apoptosis induced by these NSAIDs. We further show that sulindac sulfide and SC-'236-induced DR5 upregulation occurs independent of the COX inhibitory effects of these NSAIDs. Using Baxproficient (Bax+/7) and Bax-deficient (Bax7/7) HCT116 human colon cancer cells, we further demonstrate that Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac sulfide and SC-'236. For example, sulindac sulfide upregulates DR5 in both Baxdeficient and proficient cells, but Apo2L/TRAIL efficiently potentiates sulindac sulfide-induced apoptosis as well as activation of caspase-8, -9 and -3 only in Baxproficient cells. SC-'236 also upregulates DR5 in both Bax-proficient and Bax-deficient cells but Apo2L/ TRAIL potentiates SC-'236-mediated apoptosis and caspases-8 and -3 activation in both Bax-proficient and Bax-deficient cells. Further, in Bax-deficient cells, neither sulindac sulfide nor SC-'236 in combination with Apo2L/TRAIL effectively promotes the release of cytochrome c from mitochondria into cytosol and caspase-9 activation. Collectively, our results suggest that unlike sulindac sulfide, SC-'236 in combination with Apo2L/TRAIL can overcome Bax deficiency to induce apoptosis. These results have important clinical implications in that the tumors harboring Bax mutations are likely to develop resistance to sulindac but not to SC-'236-like NSAIDs. In conclusion, the data presented herein form the basis of future in-depth studies to further explore the utility of Apo2L/TRAIL and NSAIDs, in combination, as a novel cancer preventive/therapeutic strategy.
Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs), commonly used for their analgesic, anti-pyretic and anti-inflammatory effects, mediate their effects by inhibiting two cyclooxygenase isoenzymes, COX-1 and COX-2 (reviewed in Williams et al., 1999) . Both COX-1 and COX-2 are key enzymes that are responsible for the generation of prostaglandins from arachidonic acid (reviewed in Williams et al., 1999) . Cumulative evidence suggests that the NSAIDs, when used regularly, could reduce the risk of colon, lung, esophageal and stomach cancers (reviewed in Lancaster and Silagy, 1994; Ahnen et al., 1998; Prescott and Fitzpatrick, 2000) . Clinical trials are currently in progress to investigate the efficacy of COX-2 selective NSAIDs for prevention and treatment of colon, skin and bladder cancers. Although the molecular mechanisms of NSAID-mediated chemopreventive and antitumorigenic effects appear to be multifaceted in nature, cumulative evidence, from a number of studies, suggests that NSAIDs appear to mediate such effects by inducing apoptosis (Chan et al., 1998; Shiff et al., 1995; Zhang et al., 2000) . However, the molecular and biochemical mechanisms by which NSAIDs induce apoptosis remain to be fully elucidated.
In general, there are two well-characterized pathways of apoptosis that are termed 'extrinsic pathway' and 'intrinsic pathway' (reviewed in Ashkenazi and Dixit 1999; Schulze-Osthoff et al., 1998; Sheikh and Fornace 2000; Gross et al., 2000) . The extrinsic pathway involves the membrane death receptors such as Fas, TNF-R1, DR3, DR4 and DR5 that are activated by their respective ligands and engage the intracellular adaptor molecules, proximal caspases and the executioner caspases to mediate the apoptotic signals (reviewed in Ashkenazi and Dixit, 1999; SchulzeOsthoff et al., 1998; Sheikh and Fornace 2000) . The intrinsic pathway, also known as the mitochondrial pathway, affects mitochondrial permeability and the release of cytochrome c from mitochondria into cytosol (reviewed in Gross et al., 2000) . Cytosolic cytochrome c in association with Apaf 1 and ATP/dATP, engages the pro-caspase-9; such interactions result in the activation of caspase-9 and the downstream caspases (reviewed in Gross et al., 2000) . A large body of evidence suggests that the anti-apoptotic proteins Bcl-2 and Bcl-X L inhibit the release of cytochrome c from mitochondria into cytosol whereas Bax, Bid and Bak, the pro-apoptotic members of the Bcl-2 family, mediate the release of cytochrome c (reviewed in Gross et al., 2000) .
Recently, Zhang et al. (2000) have reported that sulindac sulfide, the major metabolite of sulindac, induced apoptosis by engaging the mitochondrial pathway in human HCT116 colon cancer cells. They further demonstrated that sulindac sulfide-mediated apoptosis was dependent on intact Bax protein since homozygous deletion of BAX gene in those cells almost completely abrogated the sulindac sulfideinduced apoptosis (Zhang et al., 2000) . We have recently reported that sulindac sulfide also engages the death receptor (DR5)-dependent apoptotic pathways (Huang et al., 2001) . We demonstrated that sulindac sulfide upregulates the expression of DR5 at both mRNA and protein levels in various colon and prostate cancer cell lines and that Apo2L/TRAIL potentiates the sulindac sulfide-induced apoptosis (Huang et al., 2001) . We also demonstrated that the abrogation of DR5-dependent apoptotic pathway, either by dominant-negative FADD (FADD-DN) or caspase-8 inhibitor, partially blocked sulindac sulfidemediated apoptosis (Huang et al., 2001) . Following the publication of our results, another group (Han et al., 2001 ) also reported that NSAIDs do engage a membrane death receptor to mediate apoptosis and that FADD-DN inhibits apoptosis induced by NSAIDs. Although Han et al. (2001) did not explore the role of DR5, they did however, rule out the involvement of other death receptors in NSAIDsmediated apoptosis. Together these results demonstrated that sulindac sulfide and other NSAIDs, in addition to engaging the mitochondrial pathway (Zhang et al., 2000) , also engaged the membrane death receptor pathway involving DR5 to mediate apoptosis (Huang et al., 2001; Han et al., 2001) .
It is now well established that the apoptotic signals originating at the death receptors can cross talk with the mitochondrial pathway via Bid, a pro-apoptotic member of the Bcl-2 family (Li et al., 1998) . For example, activation of death receptors leads to activation of proximal caspase-8. Caspase-8 has been shown to cleave Bid and the truncated Bid then translocates to mitochondria and promotes the release of cytochrome c into cytosol and thereby activates the intrinsic (mitochondrial) pathway of apoptosis (Li et al., 1998; Luo et al., 1998; Wei et al., 2000) . Recent studies have reported that Bax deficiency can also cause resistance to Apo2L/TRAIL-mediated apoptosis El-Deiry, 2001, Deng et al., 2002; LeBlanc et al., 2002) . Our recent results (Huang et al., 2001) demonstrate that sulindac sulfide engages the DR5 pathway and that Apo2L/TRAIL, a ligand of DR5, potentiates sulindac sulfide-induced apoptosis. The findings that Bax-deficient cells develop resistance to both sulindac sulfide as well as Apo2L/TRAIL appear to further support the role of DR5 in apoptosis mediated by this NSAID.
Given that sulindac sulfide engages the mitochondrial as well as DR5 pathways (Zhang et al., 2000; Huang et al., 2001 ) and the fact that Bax deficiency causes resistance to sulindac sulfide as well as Apo2L/ TRAIL, we undertook this study to investigate the effect of sulindac sulfide on DR5 expression and its interaction with Apo2L/TRAIL in Bax-deficient cells. We also sought to investigate whether a cross talk exists between sulindac sulfide activation of the DR5 and mitochondrial pathways. In addition to sulindac sulfide that is a non-selective COX inhibitor, we also investigated the effects of COX-2 selective NSAID, SC-'236 either alone or in combination with Apo2L/ TRAIL in both Bax-deficient and Bax-proficient cells.
Results
To explore the existence of a cross talk between the DR5 and mitochondrial pathways during sulindac sulfide-mediated apoptosis, we investigated the effect of sulindac sulfide on caspase-8-dependent Bid cleavage. Bid serves to bridge a cross talk between the death receptors and mitochondria in that truncated Bid translocates to mitochondria and induces the release of cytochrome c into cysotol (Li et al., 1998; Luo et al., 1998; Wei et al., 2000) . As shown in Figure 1 , sulindac sulfide induced caspase-8 activation, as is demonstrated by decreased levels of the pro-caspase-8 protein in HCT116 human colon cancer cells. As is also shown in Figure 1 , caspase-8 activation was coupled with a reduction in the levels of full-length Bid protein, indicating Bid cleavage and thereby suggesting that a potential cross talk exists between the death receptor Sulindac sulfide is known to inhibit both COX-1 and COX-2 enzymes. Next, we sought to determine whether sulindac sulfide-mediated upregulation of DR5 was dependent on its COX inhibitory effects. We selected HCT15 and HCT116 human colon cancer cell lines for further investigation since HCT15 cells do not harbor the functional COX-1 and COX-2 enzymes; whereas HCT116 cells are COX-2-deficient (Smith et al., 2000; Williams et al., 2000) . In addition to sulindac sulfide, we also used SC-'236, a COX-2 selective NSAID that does not inhibit COX-1. Sulindac sulfide and SC-'236 independently upregulated DR5 mRNA ( Figure 2 ) and protein levels (see Figure 4b ) in both HCT116 and HCT15 cells. Thus, these results suggest that (1) DR5 upregulation is not limited to sulindac sulfide but SC-'236, another NSAID, also regulates this death receptor and (2) DR5 upregulation by these two different NSAIDs occurs in a COX inhibition-independent manner.
Previously, Zhang et al. (2000) have shown that Baxdeficient HCT116 human colon cancer cells are resistant to sulindac sulfide-induced apoptosis. Next, we used the Bax-proficient (Bax +/7 ) and Bax-deficient (Bax 7/7 ) HCT116 cells to examine the effects of sulindac sulfide and SC-'236 on apoptosis and DR5 expression. As shown in Figure 3 , SC-'236 was about equally potent in inducing apoptosis in both Baxproficient and Bax-deficient cells. In contrast, Baxdeficient cells were clearly resistant to sulindac sulfideinduced apoptosis when compared to their heterozygous counterparts (Figure 3 ), which is consistent with previous findings by Zhang et al. (2000) . However, both sulindac sulfide and SC-'236 independently upregulated DR5 expression in Bax-proficient and Bax-deficient cells (Figure 4 ). Together, these results suggest that although Bax deficiency selectively confers sulindac sulfide resistance, it does not affect the ability of both NSAIDs to modulate DR5 expression and that DR5 appears to reside upstream of Bax.
Apo2L/TRAIL is a ligand of DR5. Given that sulindac sulfide or SC-'236 upregulates DR5 expression in both Bax-proficient and Bax-deficient cells, we next sought to investigate whether Apo2L/TRAIL could further enhance the effects of these agents in both Bax-proficient and Bax-deficient cells. We have previously demonstrated that sulindac sulfide (125 mM) upregulation of DR5 mRNA can be noted within 7 h in HCT116 cells and thus DR5 regulation precedes sulindac sulfide-induced apoptotic changes in these cells (Huang et al., 2001) . We have noted that SC-'236 (60 mM) also upregulated DR5 mRNA expression within 7 h in both Bax proficient and Bax-deficient cells (data not shown). As shown in Figure 5 , neither sulindac sulfide (125 mM) nor SC-'236 (60 mM) induced apoptosis within 7 h in both Bax-proficient and Baxdeficient cells. However, Bax-proficient cells were clearly more sensitive to undergo apoptosis within 7 h of Apo2L/TRAIL treatment than their Baxdeficient counterparts ( Figure 5 ). We also found that Apo2L/TRAIL significantly potentiated sulindac sulfide-induced apoptosis in Bax-proficient cells but had only a modest effect on Bax-deficient cells ( Figure  5 ). With regard to Apo2L/TRAIL and SC-'236 interactions, the extent of apoptosis induced by the combination of these two agents was quite comparable in both Bax-proficient and Bax-deficient cells ( Figure  5) . These results thus demonstrate that Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac sulfide or SC-'236 in Bax-deficient and Baxproficient cells.
Next, we explored the molecular basis of the differential effect of Apo2/TRAIL on sulindac sulfide or SC-'236-mediated apoptosis in Bax-proficient and Bax-deficient cells. The results presented in Figure 5 compare the effects of Apo2L/TRAIL plus sulindac sulfide with those of Apo2L/TRAIL plus SC-'236 on the intracellular apoptotic molecules that are engaged by extrinsic and intrinsic pathways in Bax-proficient and Bax-deficient HCT116 cells. As is shown, sulindac sulfide (125 mM) or SC-'236 (60 mM) when used alone for 7 h, did not affect pro-caspases-8, -3 and -9 or Bid in Bax-proficient ( Figure 6, lanes 1 -3) or Bax-deficient cells ( Figure 6 , lanes 10 -12), indicating that both agents, within 7 h of treatment, did not affect the extrinsic (death receptor) and intrinsic (mitochondrial) pathways. These biochemical data are consistent with our observations that both of these agents also did not induce apoptosis within 7 h of treatment ( Figure 5 ). Apo2L/TRAIL (50 ng/ml) when used alone clearly induced caspases-8, -3 and -9 activation and Bid cleavage in Bax-proficient cells within 7 h (Figure 6 , lane 5) although at the lower concentration (10 ng/ml) it had a weaker effect on these molecules ( Figure 6 , lane 4). In Bax-deficient cells, however, Apo2L/TRAIL (50 ng/ml)-induced caspases-8 and -3 activation and Bid cleavage were diminished while caspase-9 activation was abrogated ( Figure 6, lane 14) . These results are consistent with those shown in Figure 5 indicating In Bax-proficient cells, the effect of Apo2L/TRAIL plus sulindac sulfide on caspases-8, -3 and -9 and Bid cleavage was clearly stronger than that noted with Apo2L/TRAIL alone ( Figure 6 , compare lanes 4 and 5 with 8 and 9). These results are consistent with those shown in Figure 5 indicating that Apo2L/TRAIL cooperates with sulindac sulfide to induce apoptosis in Bax-proficient cells. In Bax-deficient cells, the combination of both agents rather weakly induced caspases-8 and -3 activation and Bid cleavage whereas caspase-9 activation was abolished ( Figure 6 , lanes 17 and 18). Once again, these results are consistent with those shown in Figure 5 which indicate that Apo2L/ TRAIL plus sulindac sulfide only weakly induced apoptosis in Bax deficient cells.
On the other hand, Apo2L/TRAIL (50 ng/ml) plus SC-'236 efficiently induced caspases-8 and -3 activation and Bid cleavage in both Bax-proficient and Baxdeficient cells (Figure 6, compare lanes 7 and 16) . Although both agents also induced caspase-9 activation in Bax-proficient cells, they did not do so in Baxdeficient cells (Figure 6, compare lanes 7 and 16) . It is of note that the combination of Apo2L/TRAIL and SC-'236 efficiently induced apoptosis in Bax-proficient ) HCT116 cells growing in 60 mM plates or 6-well plates were exposed to sulindac sulfide (SD) or indicated concentrations of SC-'236 (SC) and approximately 24 h later processed for apoptosis detection as described in 'Materials and methods'. The values of one representative experiment are shown Figure 5 Apo2L/TRAIL interacts with sulindac sulfide or SC-'236 to mediate apoptosis in Bax-proficient and Bax-deficient human colon cancer cells. Bax-proficient (Bax +/7 ) or Bax-deficient (Bax 7/7 ) cells were treated with vehicle alone; sulindac sulfide; SC-'236 and Apo2L/TRAIL or the combination of sulindac sulfide or SC-236 and Apo2L/TRAIL for approximately 7 h. Cells were processed for apoptosis detection as described in Materials and methods. Values represent means of two independent experiments; bars, s.e.m.
as well as Bax-deficient cells ( Figure 5 ). These results thus suggest that although Bax appeared to be required for caspase-9 activation in these cells, the lack of caspase-9 activation did not affect the apoptotic interactions between Apo2L/TRAIL and SC-'236.
To investigate whether, under these experimental conditions, cytochrome c was released from mitochondria into cytosol, we analysed the cytosolic fractions from untreated, Apo2L/TRAIL-treated and Apo2L/ TRAIL+NSAIDs-treated cells. As shown in Figure 7 , Apo2L/TRAIL (50 ng/ml) either alone or in combination with sulindac sulfide (125 mM) induced the release of cytochrome c into cytosol in Bax-proficient cells (Figure 7 , lanes 4 and 6) but had only minimal effect in Bax-deficient cells (Figure 7, lanes 10 and 12) . The combination of Apo2L/TRAIL (50 ng/ml) and SC-'236 (60 mM) also induced the release of cytochrome c into cytosol in Bax-proficient cells (Figure 7 , lane 5) but its effect was clearly diminished in Bax-deficient cells (Figure 7, lane 11) . These results thus suggest that the lack of caspase-9 activation in Bax-deficient cells by Apo2L/TRAIL, Apo2L/TRAIL plus sulindac sulfide or Apo2L/TRAIL plus SC-'236 could be a consequence of absent of diminished cytochrome c release into cytosol. ) cells were treated with vehicle alone; sulindac sulfide; SC-'-236; Apo2L/TRAIL or the combination of sulindac sulfide or SC-'236 and Apo2L/TRAIL for approximately 7 h. Cells were processed for Western blot analyses by standard procedures as described in Materials and methods. The same blots corresponding to Bax +/7 or Bax 7/7 cells were sequentially probed with indicated antibodies 
Discussion
A large body of recent evidence highlights the significance of NSAIDs as key chemoprevention and chemotherapeutic agents (reviewed in Williams et al., 1999; Lancaster and Silagy, 1994; Ahnen et al., 1998; Prescott and Fitzpatrick, 2000) . Numerous studies have shown that NSAIDs can induce apoptosis in human cancer cells of various types but the molecular and biochemical mechanisms by which NSAIDs mediate their apoptotic effects remain largely unclear (Chan et al., 1998; Shiff et al., 1995; Zhang et al., 2000) . We and others have previously demonstrated that sulindac sulfide-induced apoptosis involved activation of the DR5 and the mitochondrial signaling pathways (Huang et al., 2001; Zhang et al., 2000) . In the present study, we provide evidence that a cross talk appears to exist between these two pathways during sulindac sulfide-induced apoptosis. We show that DR5 and caspase-8 activation by sulindac sulfide is tightly associated with Bid cleavage ( Figure 1) ; Bid is a known substrate of caspase-8 and truncated Bid translocates to mitochondria to promote cytochrome c release into cytosol (Li et al., 1998; Luo et al., 1998; Wei et al., 2000) . Our data thus suggest that the DR5 signaling pathway appears to function upstream of the mitochondrial pathway and both pathways talk to each other via Bid during sulindac sulfide-induced apoptosis.
We have also investigated the involvement of the DR5 and mitochondrial signaling pathways during SC-'236-induced apoptosis. We found that SC-'236 also upregulates DR5 expression at both mRNA and protein levels and that SC-'236-induced DR5 expression is coupled with caspase-8 activation and Bid cleavage (data not shown). Thus, DR5 regulation is not limited to sulindac sulfide but SC-'236, another (COX-2 selective) NSAID, also regulates DR5 and its downstream signaling molecules. Our results also suggest that NSAID-mediated upregulation of DR5 occurs in a COX-inhibition independent manner. For example, (1) SC-'236, a COX-2 selective NSAID, upregulated DR5 expression in HCT116 cells that are known to be COX-2 deficient (Smith et al., 2000) and (2) both sulindac sulfide and SC-'236 upregulated the DR5 mRNA and protein levels in HCT15 human colon cancer cells that do not harbor COX-1 or COX-2 (Williams et al., 2000) . Given that both of these NSAIDs can induce apoptosis in HCT116 and HCT15 cells (Huang et al., 2001; Williams et al., 2000) , it is therefore, likely that the apoptosis inducing potential of these two NSAIDs is not dependent on their ability to inhibit COX enzymes. In fact a recent study (Song et al., 2002) has confirmed that the apoptosis inducing potential of various COX-2 inhibitors can be dissociated from their COX-2 inhibitory activity.
Although we noted that both sulindac sulfide and SC-'236 could independently interact with Apo2L/ TRAIL to activate the DR5 and mitochondrial pathways in Bax-proficient cells, importantly, our data also demonstrate that these two NSAIDs behaved differently in Bax-deficient cells. For example, the Baxdeficient cells are resistant to sulindac sulfide or Apo2L/TRAIL-induced apoptosis ( Figure 5 and Burns and El-Deiry 2001; Deng et al., 2002; Leblanc et al., 2002) and although sulindac sulfide upregulates DR5 in both Bax-deficient and proficient cells, the DR5 ligand, Apo2L/TRAIL could efficiently potentiate sulindac sulfide-induced apoptosis only in Bax-proficient cells but not in Bax-deficient cells. A recent study (Ravi and Bedi, 2002) has also reported that Apo2L/TRAIL potentiates sulindac sulfide-induced apoptosis in Baxproficient but not in Bax-deficient HCT116 cells. Our results further demonstrated that both sulindac sulfide and Apo2L/TRAIL, in combination, were also more effective in promoting the activation of caspases-8, -9 and -3 in Bax-proficient cells (Figures 5 and 6 ), but their effects on apoptosis and activation of caspases were significantly diminished in Bax-deficient cells (Figures 5 and 6 ). Apo2L/TRAIL alone was also less potent in inducing caspases-8 and -3 activation in Baxdeficient cells (Figure 6 ). These results suggest that Bax deficiency somehow affects the ability of Apo2L/ TRAIL to activate proximal caspase-8 and even though sulindac sulfide upregulates DR5 expression in Bax-deficient cells, the combination of Apo2L/ TRAIL and sulindac sulfide only partially overcomes that block (Figures 5 and 6 ).
SC-'236, also upregulated DR5 in both Bax-proficient and Bax-deficient cells. The combination of Apo2L/TRAIL and SC-'236 also induced caspase-8 activation and mitochondrial pathway (cytochrome c release and caspase-9 activation) in Bax-proficient cells (Figures 5 and 6 ). Unlike sulindac sulfide, however, SC-'236 in combination with Apo2L/TRAIL was found to be equally effective in mediating apoptosis ( Figure 5 ) and activating caspases-8 and -3 in Baxdeficient cells (Figure 6 ). In the same cellular background, however, the combination of sulindac sulfide and Apo2L/TRAIL was less effective in cell killing and activation of caspases-8 and -3 (Figures 5 and 6) . Further, in Bax-deficient cells, neither sulindac sulfide nor SC-'236 in combination with Apo2L/TRAIL was effective in promoting the release of cytochrome c from mitochondria into cytosol and caspase-9 activation. Collectively, our results suggest that unlike sulindac sulfide, SC-'236 in combination with Apo2L/TRAIL can overcome Bax deficiency to induce apoptosis. Thus, Apo2L/TRAIL differentially modulates, in the same Bax-deficient background the apoptotic effects of two different NSAIDs both of which independently upregulate DR5 (Figure 8 ). Based on our findings, we propose that SC-'236 appears to mediate its differential effect by promoting a strong activation of the DR5-dependent apoptotic signals (i.e. DR5 ?caspase 8?caspase?3, Figure 6 and Figure 8 ) in order to overcome the defective mitochondrial (intrinsic) pathway.
Recent studies suggest that, in addition to other mechanisms, deregulation of apoptotic cell death may also contribute to the development and progression of malignancies (reviewed in Reed, 2002; Nicholson, 2000) . There has been a considerable interest in the TRAIL/Apo2L and NSAID-mediated apoptosis in Bax deficient cells Q He et al discovery of anticancer therapeutics that would target apoptotic machinery (reviewed in Reed, 2002; Nicholson, 2000) . However, deregulated apoptotic signaling has been implicated as one of the underlying causes of tumor cell resistance to anticancer agents (reviewed in Reed, 2002; Nicholson, 2000) . Thus, a better understanding of the molecular mechanisms by which tumor cells acquire resistance to apoptosis will help develop novel and more efficacious anticancer therapies. The role of NSAIDs as anticancer agents is well established (reviewed in Williams et al., 1999) . Apo2L/TRAIL has also generated a great deal of enthusiasm since it appears to selectively target cancer cells without much systemic toxicity in animals (Walczak et al., 1999; . Our present results demonstrate that Apo2L/TRAIL differentially modulates the apoptotic effects of two different NSAIDs in Baxdeficient and Bax-proficient cells. These results could have important clinical implications for colon cancer patients. For example, it is now well documented that NSAIDs-dependent chemoprevention appears a better strategy for those who are at risk of developing colon cancer (Zhang et al., 2000 and refs. therein) . Defects in mismatch repair are believed to be part of the underlying cause of hereditary nonpolyposis colorectal cancer (Lynch and de la Chapelle, 1999) . Due to mismatch repair deficiency, colon cancer cells tend to mutate the unstable mononucleotide tracts (Ionov et al., 1993; Rampino et al., 1997) . Bax gene contains an unstable mononucleotide tract that is frequently mutated in tumors with mismatch repair deficiency (Rampino et al., 1997; Zhang et al., 2000) . Thus, our results support the notion that tumors harboring Bax mutations are likely to develop resistance to sulindac but not to SC-'236-like NSAIDs. Therefore, the colon cancer patients whose tumors have acquired Bax mutations might not respond to sulindac but could benefit from SC-'236-like agents when given either alone or in combination with Apo2L/TRAIL. In conclusion, our present study provides an insight, at the molecular levels, as to (1) how Bax deficiency leads to apoptosis resistance in tumor cells and (2) how to overcome such resistance. In addition, the data presented herein from the basis of future in-depth studies to further explore the utility of Apo2L/TRAIL and NSAIDs, in combination, as a novel cancer preventive/therapeutic strategy.
Materials and methods

Materials
Sulindac sulfide was provided by Merk (Rahway, NJ, USA) while SC-'236 was obtained from Searle/Pharmacia (Chesterfield, MO, USA). Anti-human DR5 antibody was purchased from Alexis Biochemicals (San Diego, CA, USA), Antihuman pro-caspases-8 and -9 antibodies were purchased from PharMingen (San Diego, CA, USA). The anti-human caspase-3 antibody was purchased from Transduction Laboratory (Lexington, KY, USA) while anti-human b-actin antibody was obtained from Sigma Chemical (St. Louis, MO, Figure 8 Schematic illustration of the apoptotic pathways engaged by Apo2L/TRAIL in combination with sulindac sulfide or SC-'236 in Bax-proficient and Bax-deficient cells. Sulindac sulfide upregulates DR5 and in the presence of Apo2L/TRAIL predominantly engages the intrinsic pathway via caspase-8-dependent Bid cleavage to mediate apoptosis. Sulindac sulfide plus Apo2L/ TRAIL may also engage caspase-3, albeit weakly via caspase-8. SC-'236 also upregulates DR5 but in combination with Apo2L/ TRAIL engages both the extrinsic and intrinsic pathways of apoptosis (Sheikh et al., 1998a,b; Huang et al., 2001) .
Northern and Western blotting
Standard procedure were used for RNA extraction and Northern blot analyses as we have previously described (Sheikh et al., 1994; Huang et al., 2001) . To detect DR5-specific signals, a human DR5 cDNA probe was used as previously reported (Huang et al., 2001) . Standard procedures were also used to perform Western blot analyses as we have previously described (Sheikh et al., 1998b; Huang et al., 2001) .
Preparation of cytosolic fractions
Cytosolic fractions were prepared according to a previously reported procedure (Yang et al., 1997) with modifications.
Briefly, Bax +/7 and Bax 7/7 cells growing in 100 mM plates were treated with Apo2L/TRAIL and/or NSAIDs and harvested by centrifugation at 1000 r.p.m. (GLC-2B centrifuge, SORVALL) for 5 min. Cell pellets were washed once with cold phosphate-buffered saline (PBS), resuspended in 400 ml buffer A (20 mM HEPES-KOH, pH 7.5, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM sodium EDTA, 250 mM sucrose, 1 mM sodium EGTA, 1 mM dithiothreitol, 0.4 mM phenylmethylsulfonylfluoride, 10 mg/ml aprotinin) and homogenized with 40 strokes of a Dounce Homogenizer using AB-type pestle. Cell homogenates were centrifuged at 750 g for approximately 15 min at 48C, the supernatants were recovered and centrifuged at 10 000 g for approximately 15 min at 48C. Supernatants were centrifuged one more time at 100 000 g for about 1 h at 48C and the resulting supernatants were analysed for cytochrome c by Western blotting.
